LAUSR

The present review discusses current developments and outcomes of renal transplantation in systemic amyloidosis. Amyloidosis can wreak havoc on the architecture and functioning of the kidneys, leading to end-stage renal disease. In recent years, the available treatments, especially for light-chain amyloidosis but also for several of the underlying inflammatory diseases that cause amyloid A amyloidosis have expanded leading to prolonged survival albeit frequently with renal failure. At the same time, there are also increasing numbers of patients diagnosed with one of the inherited forms of amyloidosis for which currently there is no targeted treatment available and, in some cases, renal failure is unavoidable. Due to the complex nature of the pathophysiology and treatment of these diseases, it can be very challenging for the clinician to determine whether or not it is appropriate to refer an affected individual for kidney transplantation. Determining eligibility criteria, as well as peritransplant and posttransplant management, requires a multidisciplinary approach with close monitoring and follow-up.